Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
First Trial of ILUMYA™ in Patients with Psoriatic Arthritis Met Primary Efficacy Endpoint, with No Evident Safety Concerns Over 71%...











































